COVID-19 Drug: WHO Resumes Clinical Trials Of Hydroxychloroquine

The suspension of clinical trials of hydroxychloroquine as a potential treatment for coronavirus (COVID-19) has finally been stopped by the world health organisation with the hopes that clinical drug will resume soonest

The resumption of the clinical trials of hydroxychloroquine again as a potential treatment for coronavirus (COVID-19) was announced by WHO’s Director-General, Dr Tedros Ghebreyesus.

Ghebreyesus, who stated this on the official twitter account of the UN health agency, said the hydroxychloroquine section of WHO’s Solidarity Trial can resume after being paused temporarily on May 25.

here is Ghebreyesus series of tweets below about the resumption  of the COVID-19 Drug

Based on available data, the #COVID19 Solidarity Trial Data Safety & Monitoring Committee recommended there are no reasons to modify the trial protocol. The Executive Group endorsed the continuation of all arms of the Trial, including the use of hydroxychloroquine. https://t.co/r88DVEvZ3j pic.twitter.com/cYITShxcE7

— Tedros Adhanom Ghebreyesus (@DrTedros) June 3, 2020

Last week the #COVID19 Solidarity Trial Executive Group implemented a temporary pause of the hydroxychloroquine arm of the trial, because of concerns about the safety of the drug. This decision was taken as a precaution while the safety data were reviewed.https://t.co/3mGO6fT41d

— Tedros Adhanom Ghebreyesus (@DrTedros) June 3, 2020

The trial’s Data Safety and Monitoring Committee had halted the study as a precaution in response to safety concerns raised by an observational study published in the Lancet.